Masthead small

SMFM Statement: The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth

The Society for Maternal-Fetal Medicine (SMFM) continues to recommend that all women with a prior spontaneous preterm birth (PTB) of a singleton pregnancy be offered 17-alpha hydroxyprogesterone caproate (17OHP-C) therapy in a subsequent pregnancy with a singleton gestation. Data from several sources suggest that despite these recommendations, there remains continued underutilization of 17OHP-C for eligible patients.

The purpose of this statement is to reaffirm the choice of progestogen for women with a singleton gestation and a prior spontaneous PTB.